PPT-CROI 2016

P de Truchis Nouvelles molécules Combinectine deux adnectines antiCD4 et antigp41 associées à un peptide inhibiteur de fusion cet inhibiteur dentrée a une longue durée daction et ses composants bloquent lentrée du VIH dans les cellules de façon synergique. non-AIDS Morbidity. Peter W. Hunt, MD. Associate Professor of Medicine. UCSF HIV/AIDS Division. A shift in focus…. T cell activation as a target for interventions in the pre-ART era. Monocyte activation and inflammation a target during treated HIV disease. Scott Letendre, M.D.. Professor of . Medicine and Psychiatry. University of California, San Diego. Disclosures. Funds for investigator-initiated research were paid to University of California, San Diego:. Nina Kim, MD . Associate Professor of Medicine. Division of Allergy & Infectious Diseases. University of Washington. No financial conflicts of interest. ION-4. Ledipasvir-Sofosbuvir. for 12 weeks. Animal Care and Use Working Group. Jim Moon, Donna Jarrell, Anne Clancy. MGH Executive Committee on Research (ECOR). MGH Center for Systems Biology. Misha. Pivovarov. Problem. : Need for coordinated sharing of mouse strains at MGH. Weill Cornell Medicine. New York, New York. Investigational . Antiretroviral Drugs. FORMATTED. : . 01-13-17. New York, New York: February 24, 2017 . Learning Objectives. After attending this presentation. Joseph J. Eron, Jr, MD Professor of Medicine and Epidemiology The University of North Carolina at Chapel Hill Chapel Hill, North Carolina Future Directions: Investigational Approaches to Antiretroviral Therapy 1 Queen Mary University, London, United Kingdom; 2 EPIMED GmbH, Berlin, Germany; 3 Hospital Universitario Fundación Jiménez Díaz , Madrid, Spain; 4 Central Institute of Epidemiology, Moscow, Russian Federation; Joseph J. Eron, Jr, MD. Professor of Medicine. University of North Carolina. Chapel Hill, North Carolina. Financial Relationships With Commercial Entities. Dr Eron has served as an ad hoc consultant to Janssen, ViiV Healthcare, Merck, and Gilead Sciences, Inc. His institution receives contracts for clinical research on which Dr Eron is the local principal investigator from Janssen Therapeutics, ViiV Healthcare, and Gilead Sciences, Inc. Résumé scientifique des principales études cliniques présentées à la CROI 2019. CAHR is pleased to provide this scientific summary of the major clinical studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2019). The synthesis aims to improve the cascade of care by increasing the skills and knowledge of Canadian health care professionals working in the realm of HIV. This presentation was made possible with the support of an educational grant from ViiV Healthcare.. Prediction. . of . events. . after. ART. initiation. INSTI . and IRIS ?. Test and . Treat. Same. Day. Switch DTG/ABC/3TC. to BIC/F/TAF. Miscellaneous. ART. Test and Treat the Same Day - Is this feasible ?. Brian R. Wood, MD. Assistant Professor of Medicine, University of Washington. Medical Director, NW AETC ECHO. March 5, 2015. ECHO CROI Reviews 2015. 3/5/15. 3/12/15. 3/19/15. Brian Wood: . Primary Care. Shireesha Dhanireddy. Robert Harrington. March 17, 2014. No financial conflicts of interest. Outline. Treatment Studies. Tenofovir. . alafenamide. (TAF) in a single-tablet regimen in initial HIV-1 infection . CROI Update 2016. FORMATTED: MM/DD/YY. From . H . Masur. , MD, . at Washington, DC: April 15, 2016, IAS-USA. . Oral Abstract. Estimating the Lifetime Risk of HIV Infection in the United States. Kristen Hess et al. San . Francisco Department . of Public Health. Clinical Professor of Medicine and Epidemiology. University of California San Francisco. San Francisco, California. Maximizing the Benefits of . Pre-Exposure Prophylaxis (.